VEGFR is targeted in cancer therapy through various approaches aimed at inhibiting its activity and thereby blocking tumor angiogenesis. These strategies include:
Monoclonal antibodies: Such as bevacizumab, which bind to VEGF and prevent it from interacting with VEGFR. Tyrosine kinase inhibitors (TKIs): Such as sunitinib and sorafenib, which directly inhibit the kinase activity of VEGFR. VEGF-trap: A fusion protein that acts as a decoy receptor to sequester VEGF.
